According to CNN, the shares of leading vaccine manufacturers plummeted on Thursday after President-elect Donald Trump ...

Looking at options history for BioNTech BNTX we detected 11 trades. If we consider the specifics of each trade, it is ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $5.5 billion in 2024. Pfizer expects full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenue.

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, approximately $5B and $5.5B, respectively. Including the contribution ...